Citations

Clear

9383 citation(s) found for "Thomas, PS".

Genomic Susceptibility Loci for Brain Atrophy in Hypertensive Sibships From the GENOA Study
Fornage, Myriam , Jack, Clifford R. , Kardia, Sharon L. R., Boerwinkle, Eric , Turner, Stephen T. , Mosley, Thomas H. , Andrade, Mariza de , Jack, Clifford R

Mayo Clinic

Hypertension | February 8, 2005 | Volume: 45 | Issue: 4 | Pages: 793-798

10.1161/01.hyp.0000154685.54766.2d | PMID 15699467 Get It

We measured 366 microsatellite markers genome-wide to search for loci contributing to subcortical white matter ischemic damage (leukoariosis) and brain atrophy in 488 non-Hispanic white subjects (193 men, 295 women; mean age±SD=64.1±7.7 years; 79% hypertensive) from 223 sibships recruited through ≥2 members with essential hypertension diagnosed before age 60. Leukoariosis was quantitated by magnetic resonance imaging (MRI), brain atrophy by the difference between intracranial and brain volumes, and calculated mean arterial pressure and pulse pressure provided measures of steady-state level and pulsatile components of blood pressure. After adjustment for sex and age, variance components models estimated significant heritability of leukoariosis (0.72), brain atrophy (0.52), mean arterial pressure (0.084), and pulse pressure (0.294) ( P <0.0001 for each trait). Univariate maximum logarithm of odds scores (MLS) were observed for leukoariosis on chromosome 5 (MLS=1.91; P =0.00150); for brain atrophy on 1q and 17p (MLS=2.76, P =0.00018); for mean arterial pressure on 11p (MLS=1.57; P =0.00354); and for pulse pressure on 11p (MLS=3.02; P =0.00070). Bivariate linkage analyses provided evidence of loci with pleiotropic effects on brain atrophy and pulse pressure on chromosomes 11p (MLS = 5.07 at 16 cM; P =0.00001) and 16q (MLS of 4.56 at 124 cM; P =0.00003). These results demonstrate usefulness of multivariate linkage analyses to detect loci with pleiotropic effects on genetically correlated traits and suggest overlap between the genes influencing blood pressure and those contributing to brain atrophy.
Clinical Presentation, Investigation, and Management of Pulmonary Vein Stenosis Complicating Ablation for Atrial Fibrillation
Packer, Douglas L. , Keelan, Paul C., Munger, Thomas M. , Breen, Jerome F., Asirvatham, Sam, Peterson, Laura A., Monahan, Kristi H. , Hauser, Mary F., Chandrasekaran, Krishnaswamy , Sinak, Lawrence J., Holmes, David R. , Asirvatham, Samuel J. , Asirvatham, Samuel J

Mayo Clinic

Circulation | February 7, 2005 | Volume: 111 | Issue: 5 | Pages: 546-554

10.1161/01.cir.0000154541.58478.36 | PMID 15699274 Get It

Background— Although segmental or circumferential ablation is effective in eliminating pulmonary vein (PV)–mediated atrial fibrillation (AF), this procedure may be complicated by the occurrence of PV stenosis. Methods and Results— To establish the clinical presentation, diagnostic manifestations, and interventional management of PV stenosis, 23 patients with stenosis of 34 veins complicating ablation of AF were evaluated. Each patient became symptomatic 103±100 days after undergoing ablation. In 8 veins, the ablation producing the PV stenosis was a repeated procedure for continued AF. Nineteen patients presented with dyspnea on exertion, 7 with dyspnea at rest, 9 with cough, and 6 with chest pain. On multirow spiral computed tomography examination, the narrowest lumen of the affected PVs measured 3±2 mm compared with 13±3 mm at baseline ( P ≤0.001). The relative perfusion of affected lung segments on isotope scans was reduced to 4±3% of total perfusion compared with 22±10% in unaffected segments. At percutaneous intervention, these veins showed 80±13% stenosis, with a mean gradient of 12±5 mm Hg. This was significantly reduced to a residual stenosis of 9±8% ( P ≤0.001) and a residual gradient of 3±4 mm Hg ( P ≤0.001). Twenty veins were treated with balloon dilatation alone, whereas 14 veins were stented with standard 10-mm-diameter bare-metal stents. Although the symptomatic response was nearly immediate and impressive, 14 patients developed in-stent or in-segment restenosis, requiring repeated interventions in 13. Conclusions— Percutaneous intervention produces rapid and dramatic symptom relief in patients with highly symptomatic PV stenosis after radiofrequency ablation for AF. Nevertheless, alternative treatment methods will be required to decrease recurrent in-stent or in-segment restenosis.
Integrative Tumor Board: Medical and Surgical Oncology Approach
Hogan, Thomas F., Lamm, Donald L.

Mayo Clinic

Integrative Cancer Therapies | February 2, 2005 | Volume: 4 | Issue: 1 | Pages: 50-52

10.1177/1534735404274349 Get It

Nephron Distribution of Total Low Km Cyclic AMP Phosphodiesterase in Mouse, Rat and Rabbit Kidney.
Yoshida, Izumi, Takeda, Shigeyuki, Homma, Sumiko, Yusufi, Ahad Noor Khan , Douša, Thomas P., Asano, Yasushi, Kusano, Eiji

Mayo Clinic

The Tohoku Journal of Experimental Medicine | February 2, 2005 | Volume: 193 | Issue: 3 | Pages: 207-220

10.1620/tjem.193.207 | PMID 11315768 Get It

National Study of Physician Awareness and Adherence to Cardiovascular Disease Prevention Guidelines
Mosca, Lori, Linfante, Allison H., Benjamin, Emelia J. , Berra, Kathy, Hayes, Sharonne N. , Walsh, Brian W., Fabunmi, Rosalind P., Kwan, Johnny S. H., Mills, Thomas C. , Simpson, Susan Lee, Benjamin, Emelia J , Hayes, Sharonne N

Mayo Clinic

Circulation | February 1, 2005 | Volume: 111 | Issue: 4 | Pages: 499-510

10.1161/01.cir.0000154568.43333.82 | PMID 15687140 Get It

Background— Few data have evaluated physician adherence to cardiovascular disease (CVD) prevention guidelines according to physician specialty or patient characteristics, particularly gender. Methods and Results— An online study of 500 randomly selected physicians (300 primary care physicians, 100 obstetricians/gynecologists, and 100 cardiologists) used a standardized questionnaire to assess awareness of, adoption of, and barriers to national CVD prevention guidelines by specialty. An experimental case study design tested physician accuracy and determinants of CVD risk level assignment and application of guidelines among high-, intermediate-, or low-risk patients. Intermediate-risk women, as assessed by the Framingham risk score, were significantly more likely to be assigned to a lower-risk category by primary care physicians than men with identical risk profiles ( P <0.0001), and trends were similar for obstetricians/gynecologists and cardiologists. Assignment of risk level significantly predicted recommendations for lifestyle and preventive pharmacotherapy. After adjustment for risk assignment, the impact of patient gender on preventive care was not significant except for less aspirin ( P <0.01) and more weight management recommended ( P <0.04) for intermediate-risk women. Physicians did not rate themselves as very effective in their ability to help patients prevent CVD. Fewer than 1 in 5 physicians knew that more women than men die each year from CVD. Conclusions— Perception of risk was the primary factor associated with CVD preventive recommendations. Gender disparities in recommendations for preventive therapy were explained largely by the lower perceived risk despite similar calculated risk for women versus men. Educational interventions for physicians are needed to improve the quality of CVD preventive care and lower morbidity and mortality from CVD for men and women.
Rituximab Therapy for Patients With Newly Diagnosed, Advanced-Stage, Follicular Grade I Non-Hodgkin's Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group
Vukov, Allen M., Geyer, Susan M. , Kurtin, Paul J. , Friedenberg, William R., White, William L. , Chalchal, Haji , Flynn, Patrick J. , Fitch, Thomas R., Welker, Debra A., Witzig, Thomas E. , Habermann, Thomas M.

Mayo Clinic

Journal of Clinical Oncology | January 19, 2005 | Volume: 23 | Issue: 6 | Pages: 1103-1108

10.1200/jco.2005.12.052 | PMID 15657404 Get It

Purpose Patients with newly diagnosed, advanced-stage, follicular grade 1 non-Hodgkin's lymphoma (NHL) are often asymptomatic and can be observed without immediate chemotherapy. The goals of this study were to assess the overall response rate (ORR) to rituximab in this patient population and to determine the time-to-progression (TTP) and time-to-subsequent-chemotherapy (TTSC). Patients and Methods Eligible patients had untreated follicular grade 1 NHL, and measurable stage III/IV disease. Patients received rituximab 375 mg/m2 intravenous weekly × 4 doses and were then followed for response and progression; no maintenance therapy was provided. Results Thirty-seven patients were accrued; one patient was ineligible. The median age was 59 years (range, 29 to 83 years). Six patients (18%) had elevated lactate dehydrogenase levels. The ORR was 72%, with 36% complete remissions. Fourteen (39%) of 36 patients remain in unmaintained remission, two died without disease progression, and three died with disease progression. Twenty (56%) of 36 patients have disease progression. The median TTP was 2.2 years (95% CI, 1.3 to not yet reached). Eighteen patients have subsequently been treated with chemotherapy, with a median TTSC of 2.3 years (95% CI, 1.6 to not yet reached). Patients with a high lactate dehydrogenase level had a lower ORR of 33% and a short TTP of only 6 months. Conclusion Rituximab can be safely administered to patients with advanced-stage follicular grade 1 NHL with efficacy and minimal toxicity. This therapy is highly active and offers an acceptable alternative to observation in this patient population. Patients with high LDH should not be considered for rituximab monotherapy.
Letter Regarding Article by Gazzaruso et al, “Relationship Between Erectile Dysfunction and Silent Myocardial Ischemia in Apparently Uncomplicated Type 2 Diabetic Patients”
Jackson, Graham, Solomon, Hemant, Wierzbicki, Anthony S.

Mayo Clinic

Circulation | January 18, 2005 | Volume: 111 | Issue: 2 | Pages: No page available

10.1161/01.cir.0000152482.71628.51 | PMID 15657383 Get It

TIEG1 Null Mouse-Derived Osteoblasts Are Defective in Mineralization and in Support of Osteoclast Differentiation In Vitro
Subramaniam, Malayannan , Gorny, Genevieve, Johnsen, Steven A. , Evans, Glenda L., Fraser, Daniel G., Rickard, David J., Rasmussen, Kay, Deursen, Jan M. A. van, Turner, Russell T. , Oursler, Merry Jo, Spelsberg, Thomas C., Woodard, Genevieve A. , Monroe, David G. , Johnsen, Steven A

Mayo Clinic

Molecular and Cellular Biology | January 18, 2005 | Volume: 25 | Issue: 3 | Pages: 1191-1199

10.1128/mcb.25.3.1191-1199.2005 | PMID 15657444 Get It

Approval of the MERCI Clot Retriever
Becker, Kyra J. , Brott, Thomas G.

Mayo Clinic

Stroke | January 14, 2005 | Volume: 36 | Issue: 2 | Pages: 400-403

10.1161/01.str.0000153056.25397.ff | PMID 15653576 Get It

Proteomic analysis of mantle-cell lymphoma by protein microarray
Leontovich, Alexey A. , Loegering, David A., Dai, Nga T., Krajnik, Kelly L., Stenson, Mary, Melhem, Mona F., Novak, Anne J. , Ansell, Stephen M. , Ghobrial, Irene M. , McCormick, Daniel , Kaufmann, Scott H. , Witzig, Thomas E.

Mayo Clinic

Blood | January 14, 2005 | Volume: 105 | Issue: 9 | Pages: 3722-3730

10.1182/blood-2004-10-3999 | PMID 15650054 Get It

Abstract Mantle-cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin lymphoma (NHL) that behaves aggressively and remains incurable. In order to understand the pathogenesis of MCL and design new therapies, it is important to accurately analyze molecular changes in pathways dysregulated in MCL. We used antibody microarrays to compare patterns of protein expression between CD19+ purified B lymphocytes from normal tonsil and 7 cases of histologically confirmed MCL. Protein overexpression was defined as a higher than 1.3-fold or 2-fold increase in at least 67% of tumor samples compared with normal B-cell control. Of the polypeptides, 77 were overexpressed using the higher than 1.3-fold cutoff, and 13 were overexpressed using the 2-fold cutoff. These included cell cycle regulators (regulator of chromosome condensation 1 [RCC1], murine double minute 2 [MDM2]), a kinase (citron Rho-interacting kinase [CRIK]), chaperone proteins (heat shock 90-kDa protein [Hsp90], Hsp10), and phosphatase regulators (A-kinase anchor protein 1 [AKAP149], protein phosphatase 5 [PP5], and inhibitor 2). The elevated expression of some of these polypeptides was confirmed by immunoblotting and immunohistochemistry, whereas elevated expression of others could not be confirmed, illustrating the importance of confirmatory studies. This study describes a novel technique that identifies proteins dysregulated in MCL.